# Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

Study · id `cardio:ct-nct02721888` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02721888](<https://clinicaltrials.gov/study/NCT02721888>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02721888

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 127 participants.

## Technical summary

Registry record NCT02721888. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2019-10-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 127 participants (enrolled count; ClinicalTrials.gov record NCT02721888, source copy `cardio:ctgov-nct02721888-2026-02-06`, retrieved 2026-10-26)
- Started: 2012-07-10 (actual) (ClinicalTrials.gov record NCT02721888, source copy `cardio:ctgov-nct02721888-2026-02-06`, retrieved 2026-10-26)
- Primary completion: 2019-10-02 (actual) (ClinicalTrials.gov record NCT02721888, source copy `cardio:ctgov-nct02721888-2026-02-06`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: France (ClinicalTrials.gov record NCT02721888, source copy `cardio:ctgov-nct02721888-2026-02-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02721888-2026-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
- Acronym: LIRA-NAFLD/LIP
- Condition: Type 2 Diabetes
- Intervention (Drug): Liraglutide
- Intervention (Drug): MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
- Intervention (Biological): Blood sample
- Intervention (Other): Kinetic substudy (10 patients)
- Lead sponsor: Centre Hospitalier Universitaire Dijon
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 5be24d74b5d2758a46dba7ae1af7e5002fd4135f81960c3e7e200d77a4c580cf
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
